IMpower150 was one of the few immunotherapy-containing trials to include an ALK population and suggested benefit, as single-agent immunotherapy was not shown to be effective for ALK patients, probably due to their tendency to be non-smokers, with low tumor mutational burden and a unique non-inflamed oncogene-driven phenotype (56). This evidence concerns the gene ALK and neoplasm.